← FDA DRUG APPROVALS

FDA ANDA · ANDA203802

PALIPERIDONE

Sponsor: RK PHARMA

APPLICATION
ANDA203802
TYPE
ANDA
ORIGINAL APPROVAL
2015-09-24
LATEST ACTION
2020-05-29
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

PALIPERIDONEDiscontinued
PALIPERIDONE 6MG · TABLET, EXTENDED RELEASE · ORAL
PALIPERIDONEDiscontinued
PALIPERIDONE 1.5MG · TABLET, EXTENDED RELEASE · ORAL
PALIPERIDONEDiscontinued
PALIPERIDONE 9MG · TABLET, EXTENDED RELEASE · ORAL
PALIPERIDONEDiscontinued
PALIPERIDONE 3MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2020-05-29Labeling · Supplement 9 · standardAP
2020-05-29Labeling · Supplement 5 · standardAP
2020-05-29Labeling · Supplement 6 · standardAP
2020-05-29Labeling · Supplement 13 · standardAP
2020-05-29Labeling · Supplement 11 · standardAP
2015-09-24UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →